Press Release - July 25, 2017
Heidelberg, Germany, July 25, 2017 – Affimed N.V. (Nasdaq: AFMD) today announced that on August 1, 2017, the Company will release its financial results for the quarter ended June 30, 2017. The Company’s management team will host a conference call to discuss the Company’s financial results and recent corporate developments on Tuesday, August 1, 2017 at 8:30 a.m. ET. The call can be accessed by dialing one of the numbers listed below five minutes prior to the start of the call and providing the confirmation code 3489551.
Local – Amsterdam, the Netherlands: +31 (0)20 716 8257
Local – Copenhagen, Denmark: +45 32 71 16 58
Local – Frankfurt, Germany: +49 (0)69 2222 10628
Local – Geneva, Switzerland: +41 (0)22 567 5431
Local – London, U.K.: +44 (0)20 3427 1917
Local – New York City, U.S.A.: +1 212 444 0896
Local – Paris, France: +33 (0)1 76 77 22 21
An audio webcast of the conference call can be accessed in the Webcasts section on the Affimed website. A replay of the webcast will be available on Affimed’s website shortly after the conclusion of the call and will be archived on the Affimed website for 30 days following the call.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Caroline Stewart, Head IR
Phone: +1 347 394 6793
E-Mail: email hidden; JavaScript is required or email hidden; JavaScript is required
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: email hidden; JavaScript is required